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Abstract
 
A novel polymorphism in the extracellular domain 2 (EC2)
of Fc
 
g
 
RIIIA affects ligand binding by natural killer (NK)
cells and monocytes from genotyped homozygous normal
donors independently of receptor expression. The noncon-
servative T to G substitution at nucleotide 559 predicts a
change of phenylalanine (F) to valine (V) at amino acid po-
sition 176. Compared with F/F homozygotes, Fc
 
g
 
RIIIa ex-
pressed on NK cells and monocytes in V/V homozygotes
bound more IgG1 and IgG3 despite identical levels of recep-
tor expression. In response to a standard aggregated human
IgG stimulus, Fc
 
g
 
RIIIa engagement on NK cells from V/V
(high-binding) homozygotes led to a larger rise in [Ca
 
2
 
1
 
]
 
i
 
, a
greater level of NK cell activation, and a more rapid induc-
tion of activation-induced cell death (by apoptosis). Investi-
gation of an independently phenotyped normal cohort re-
vealed that all donors with a low binding phenotype are F/F
homozygotes, while all phenotypic high binding donors have
at least one V allele. Initial analysis of 200 patients with SLE
indicates a strong association of the low binding phenotype
with disease, especially in patients with nephritis who have
an underrepresentation of the homozygous high binding
phenotype. Thus, the Fc
 
g
 
RIIIa polymorphism at residue
176 appears to impact directly on human biology, an effect
which may extend beyond autoimmune disease character-
ized by immune complexes to host defense mechanisms. (
 
J.
Clin. Invest.
 
 1997. 100:1059–1070.) Key words: receptors, Fc 
 
•
 
polymorphism, genetics 
 
•
 
 macrophages 
 
•
 
 killer cells, natu-
ral 
 
•
 
 lupus erythematosus, systemic
 
Introduction
 
Genetic polymorphisms of human Fc
 
g
 
RIIa and Fc
 
g
 
RIIIb have
been characterized (1–13) and associated with certain disease
risks (14–20). The two allelic forms of Fc
 
g
 
RIIa differ by two
nucleotides (nt),
 
1
 
 one in the first extracellular Ig-like domain
(EC1) predicting a glutamine (Q) to tryptophan (W) at residue
position 27 and one in the second extracellular Ig-like domain
(EC2) predicting an arginine (R) to histidine (H) at residue
position 131. The change at position 131 markedly alters the
ability of the receptor to bind human IgG2 (10, 12), and this
polymorphism has been associated with certain bacterial infec-
tions (14, 15, 19) and with SLE (16–18). The two allelic forms of
neutrophil-specific Fc
 
g
 
RIIIb differ by five nucleotides which
results in four amino acid differences in EC1 (21). Although
binding of IgG does not seem to be affected (9), these two al-
lelic forms do have different levels of quantitative function (9,
10), and the more active NA1 allele has been associated with
severe renal disease in certain systemic vasculitides (20).
Several recent observations suggest that Fc
 
g
 
RIIIa, which is
expressed on natural killer (NK) cells, mononuclear phago-
cytes, and renal mesangial cells (22), might also be polymor-
phic in both its structure and quantitative expression. Vance
and Guyre originally described a functional polymorphism in
Fc
 
g
 
RIIIa on NK cells among normal donors (23). Based on
some differences both in IgG binding and in anti-CD16 reac-
tivity, they suggested that variations in receptor expression
might explain their observations. More recently, de Haas and
colleagues have described a triallelic sequence polymorphism
at nt 230 in Fc
 
g
 
RIIIA (24). This single nucleotide substitution
in the third exon encoding EC1 predicts an amino acid change
from leucine (L) to arginine (R) or from leucine (L) to histi-
dine (H) and reportedly influences the binding of human IgG
and several anti-CD16 mAbs (24, 25). Such structural variants
of Fc
 
g
 
RIIIa, recognized by altered patterns of anti-CD16 mAb
binding, may be related to a clinical phenotype of repeated in-
fections (26).
The Fc
 
g
 
RIIIA sequence polymorphism on NK cells which
reportedly influences ligand binding (24) raised the possibility
that this sequence polymorphism might explain previously de-
scribed differences in NK Fc
 
g
 
RIIIa and NK cell function (23,
26). To test this hypothesis, we identified several of the normal
donors studied by Vance and Guyre (23) and characterized the
nucleotide sequence of their Fc
 
g
 
RIIIA. Contrary to our ex-
pectation, these donors were monomorphic at nt 230 and nt
248 (amino acid positions 66 and 72).
 
2
 
 However, they were
polymorphic at nt 559, a site noted by Ravetch and Perussia as
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1. 
 
Abbreviations used in this paper:
 
 ADCC, antibody-dependent cel-
lular cytotoxicity; EC, extracellular domain; GAM, goat anti–mouse
IgG; MNC, mononuclear cells; NK, natural killer; nt, nucleotide; PE,
phycoerythrin; PI, propidium iodide; TC, tri-color.
2. The first amino acid of the signal sequence is designated amino acid
1 (21). In this nomenclature, nt 559, 230, and 248 are in the codons for
amino acids 176, 66, and 72, respectively. Using the first amino acid of
EC1, others have designated nt 230 and 248 polymorphisms as amino
acids 48 and 64.
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potentially polymorphic (21). This nonconservative T to G
substitution predicts a change of phenylalanine (F) into valine
(V) at position 176 in the membrane-proximal EC2. Since sev-
eral studies suggest that the second Ig-like domain strongly in-
fluences ligand binding (27–32), we pursued further character-
ization of this 176F/V polymorphism by identifying normal
donors homozygous at position 176 (and homozygous at posi-
tions 66 and 72). Compared with F/F homozygotes, Fc
 
g
 
RIIIa
expressed in V/V homozygotes bound more IgG1 and IgG3
despite identical levels of receptor expression. These observa-
tions indicate that the sequence polymorphism at nt position
559 alters the apparent affinity of Fc
 
g
 
RIIIa on both NK cells
and monocytes for IgG. This difference affects the ability of
the receptor to initiate a range of cell programs in response to
a standard stimulus and underlies the previously described
variation in NK Fc
 
g
 
RIIIa function (23). Initial analysis of 200
patients with SLE indicates a strong association of the low
binding phenotype with disease, especially nephritis, and a cor-
responding underrepresentation of the homozygous high bind-
ing phenotype. Thus, this polymorphism appears to impact di-
rectly on human biology, an effect which may well extend
beyond autoimmune disease characterized by circulating im-
mune complexes.
 
Methods
 
Donors.
 
Anticoagulated peripheral blood was obtained from healthy
normal volunteers and from 200 patients fulfilling the revised criteria
of the American College of Rheumatology for SLE (33). All studies
were reviewed and approved by each Institutional Review Board and
all donors provided written informed consent.
 
Reagents.
 
Human IgG (hIgG) subclass proteins were obtained
from The Binding Site (San Diego, CA) or Sigma Chemical Co. (St.
Louis, MO). All mAbs used were murine origin. Anti–human CD56-
phycoerythrin (PE), anti–human CD14-tri-color (TC), anti–human
CD3-FITC, anti-CD25-FITC, and anti-CD33-FITC were from Caltag
Laboratories (Burlingame, CA). Anti-Fc
 
g
 
RI (mAb 197, mIgG2a and
mAb 22.2, mIgG1), anti-Fc
 
g
 
RII (mAb IV.3, mIgG2b), and anti-
Fc
 
g
 
RIII (mAb 3G8-FITC, mIgG1) were from Medarex Inc. (Annan-
dale, NJ). Other anti-Fc
 
g
 
RIII mAbs used in this study were CLBFc
Rgran1 (mIgG2a), B73.1 (mIgG1), 1D3 (mIgM), MEM154 (mIgG1),
30.2 (mIgG1), 214.1 (mIgG1), 135.9 (mIgG1), GRM1 (mIgG2a), and
Leu11a (mIgG1). 1D3, MEM154, and CLBFcRgran1 were obtained
through the 5
 
th
 
 Leukocyte Typing Workshop. mAbs 30.2, 214.1, and
135.9 were generously provided by Dr. Howard Fleit (SUNY, Stony
Brook, NY) (34); mAb GRM1 was from Research Diagnostics Inc.
(Flanders, NJ). B73.1 (Leu11a) and Leu11a-FITC were obtained from
Becton Dickinson Immunocytometry Systems (San Jose, CA). FITC-
conjugated and unconjugated goat anti–mouse IgG(H 
 
1 
 
L) (GAM),
which recognizes mIgG1, IgG2a, and mIgM, was obtained from Boeh-
ringer Mannheim (Indianapolis, IN) and Jackson ImmunoResearch
(West Grove, PA). Heat-aggregated human IgG was prepared by in-
cubating the hIgG (Sigma), 20 mg/ml, at 63
 
8
 
C for 20 min.
 
Mononuclear cell (MNC) and NK cell preparation.
 
Fresh antico-
agulated blood was diluted 1:1 in Hanks’ buffer (GIBCO BRL,
Gaithersburg, MD) and centrifuged through a discontinuous two-step
Ficoll-Hypaque gradient in 50-ml conical tubes (35). MNC were har-
vested from the upper and neutrophils from the lower Ficoll-Hypaque
interface and washed three times with PBS, pH 7.4. After the last
wash, the cells were resuspended, counted, and used either for
mRNA preparations, for quantitative flow cytometry, or for further
purification of NK cells.
NK cells were purified with the NK Cell Isolation Kit (Miltenyi
Biotec Inc., Auburn, CA) which depletes human T cells, B cells, and
myeloid cells from MNC by magnetic separation. Isolated NK cells
were washed with Ca
 
2
 
1
 
- and Mg
 
2
 
1
 
-free PBS, pH 7.4, and assayed for
purity by flow cytometry with either the combination of anti-CD3-
FITC, anti-CD14-TC, and anti-CD56-PE or the combination of 3G8-
FITC, anti-CD14-TC, and anti-CD56-PE. Starting with 5 
 
3
 
 10
 
7
 
 MNC,
the yield of NK was typically 4–5 
 
3
 
 10
 
6
 
 total cells with a purity of
 
. 
 
85%. The efficiency of NK cell recovery was 
 
z 
 
75%.
 
Nucleic acid isolation.
 
Total RNA was isolated from 10
 
7
 
 MNC by
using TRIzol™ total RNA isolation reagent (GIBCO BRL). 5 
 
m
 
g of
total MNC RNA was used to synthesize cDNA with the SuperScript™
preamplification system (GIBCO BRL). For sequencing of genomic
DNA and for allele-specific PCR, genomic DNA was isolated using
the Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN).
 
RT-PCR and cDNA sequencing.
 
To facilitate heterozygote de-
tection, a dye primer strategy was used for fluorescence-based auto-
mated cycle sequencing of PCR product on an ABI 377 (ABI PRISM™
Dye Primer Cycle Sequencing -21M13 FS and M13REV FS Ready
Reaction Kits; Applied Biosystems, Inc., Foster City, CA). Two over-
lapping sets of primers, with either M13 universal or reverse primer
sequences at the appropriate 5
 
9
 
 ends, were designed for the Fc
 
g
 
RIIIA
cDNA. Sequencing set 4 (Fig. 1) was used to amplify position 50 to
position 414: forward 5
 
9
 
-CAG GAA ACA GCT ATG ACC TCC
CAA CTG CTC TGC TAC TT-3
 
9
 
 and reverse 5
 
9
 
-TGT AAA ACG
ACG GCC AGT CCT CAG GTG AAT AGG GTC TTC-3
 
9
 
. Se-
quencing set 3 (Fig. 1) was used to amplify position 328 to position
869: forward 5
 
9
 
-TGT AAA ACG ACG GCC AGT CCG GTG CAG
CTA GAA GTC CA-3
 
9
 
 and reverse 5
 
9
 
-CAG GAA ACA GCT ATG
ACC GGG GTT GCA AAT CCA GAG AA-3
 
9
 
. The PCR products
were purified with the QIAquick Gel Extraction Kit (QIAGEN Inc.,
Chatsworth, CA).
 
Allele-specific PCR.
 
Three primers were designed for allele-spe-
cific PCR for genotyping genomic DNA at position 559 in Fc
 
g
 
RIIIA
(PCR set 1, Fig. 1 
 
A
 
). The Fc
 
g
 
RIIIA-specific forward primer (5
 
9
 
-
TCA CAT ATT TAC AGA ATG GCA ATG G-3
 
9
 
) corresponds to
the Fc
 
g
 
RIIIA sequence between position 449 and position 473 and
was used in both T allele–specific and G allele–specific PCR assays.
The reverse primers, corresponding to nt 586–559, provided allele
specificity. The nt 559 G-specific reverse primer (5
 
9
 
-TCT CTG AAG
ACA CAT TTC TAC TCC CTA C-3
 
9
 
) differs in one nucleotide from
T-specific reverse primer (5
 
9
 
-TCT CTG AAG ACA CAT TTC TAC
TCC CTA A-3
 
9
 
) at the 3
 
9
 
 end. The allele-specific PCR product of 138 bp
was assayed on a 3% agarose gel. The PCR reaction was performed
in a GeneAmp 2400 PCR System with 360 ng of DNA, 200 nM of
each primer, 200 
 
m
 
M of dNTPs, 1.5 mM of MgCl, and 2.5 U of 
 
Taq
 
polymerase (Boehringer-Mannheim Biochemicals) in a 50-
 
m
 
l reaction
volume starting with 95
 
8
 
C for 5 min, 35 cycles of denaturing at 94
 
8
 
C
for 30 s, annealing at 51
 
8
 
C for 45 s, and extension at 72
 
8
 
C for 20 s with
a final extension at 72
 
8
 
C for 7 min. The appearance of the 138-bp
PCR products in the T or G allele–specific reaction indicates the
presence of that allele.
 
Genomic DNA sequencing.
 
To confirm Fc
 
g
 
RIIIA genomic se-
quence, primers were designed to amplify a portion of exon 4 of
Fc
 
g
 
RIIIA which corresponds to EC2 (sequencing set 1, Fig. 1 
 
A
 
).
The forward primer (5
 
9
 
-TGT AAA ACG ACG GCC AGT TCA
TCA TAA TTC TGT CTT CT-3
 
9
 
, corresponding to nt 486–505) in-
cludes an intentional mismatch six nucleotides from the 3
 
9
 
 end to pro-
vide Fc
 
g
 
RIIIA-specific priming. The reverse primer (5
 
9
 
-CAG GAA
ACA GCT ATG ACC CTT GAG TGA TGG TGA TGT TCA-3
 
9
 
)
corresponds to nt 610–590. The 162-bp PCR product containing the
nt 559 polymorphic site was purified from a 3% agarose gel with the
QIAquick Gel Extraction Kit. Fluorescence-based automated cycle
sequencing of PCR product was performed on an ABI 377 (ABI
PRISM™ Dye Primer Cycle Sequencing -21M13 FS and M13REV FS
Ready Reaction Kits).
To determine the Fc
 
g
 
RIIIA genomic sequence of EC1, primers
were designed to amplify a portion of exon 3 encompassing nt posi-
tions 230 and 248 (sequencing set 2, Fig. 1 
 
A
 
). The forward primer
(5
 
9
 
-CAG GAA ACA GCT ATG ACC CTC TTT CTG TAG CTT
GGT TC-3
 
9
 
) anneals to the intron region between S1 and S2 of the
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Fc
 
g
 
RIIIA gene. The reverse primer (5
 
9
 
-TGT AAA ACG ACG GCC
AGT ATG GAC TTC TAG CTG CAC-3
 
9
 
) corresponds to nt 348 to
331 in exon 3. The PCR product was purified and sequenced as de-
scribed above.
 
Flow cytometric assay for human IgG binding.
 
Human IgG bind-
ing assays were performed using anticoagulated, washed whole blood.
Mouse mAbs were used either for direct immunofluorescence (Leu11a-
FITC, 3G8-FITC) or for indirect immunofluorescence (3G8, Gran1,
B73.1, 1D3, MEM154, 30.2, 214.1, 135.9, GRM1) in conjunction with
FITC-labeled F(ab
 
9
 
)
 
2
 
 GAM. Human IgG subclass myeloma proteins
(IgG1, IgG2, IgG3, and IgG4) were directly conjugated with FITC ac-
cording to standard techniques (36). Aggregates were removed by ul-
tracentrifugation and removal was confirmed by the lack of binding
of the FITC-labeled myelomas to human neutrophils. Before each ex-
periment, the flow cytometer (FACScan
 
®
 
; Becton-Dickinson Immu-
nocytometry) was calibrated with quantitative fluorescein microbeads
(Flow Cytometry Standards Corp., Research Triangle Park, NC). Iden-
tification of individual cell populations was based on forward and
right angle light scattering in combination with three-color immuno-
fluorescence using TC, PE, and FITC.
For each IgG binding assay, 3 ml of heparinized whole blood was
washed and cytophilic IgG was removed by incubation in 45 ml of
PBS at 37
 
8
 
C for 20 min. For direct immunofluorescence, 100-
 
m
 
l ali-
quots of the washed whole blood were incubated at 4
 
8
 
C for 1 h with
an hIgG-FITC myeloma protein (final concentrations of 15 and 30
 
m
 
g/ml) or with anti-CD16 mAb [either directly FITC-conjugated or
indirectly with F(ab
 
9
 
)
 
2
 
 GAM IgG-FITC, see below] and with CD14-
TC and CD56-PE at 5 
 
m
 
g/ml. NK cells were identified as CD56-PE
positive, CD14-TC negative cells within the lymphocyte light scatter
gate; the binding of the different human IgG subclasses or the differ-
ent anti-CD16 mAbs was assessed by the intensity of FITC fluores-
cence. Blood monocytes were identified as CD14-TC positive, CD56-
negative cells within the typical blood monocyte light scatter gate. For
myeloma protein binding to monocyte Fc
 
g
 
RIIIa, washed whole blood
was preincubated at 4
 
8
 
C for 10 min with mAb 197 IgG (10 
 
m
 
g/ml) to
block the ligand binding site of Fc
 
g
 
RI (12).
For the anti-CD16 mAb panel assay, washed whole blood cells
were incubated with a saturating concentration of primary mAb for
30 min, washed twice with PBS, incubated with FITC-conjugated goat
F(ab
 
9
 
)
 
2
 
 anti–mouse IgG at 4
 
8
 
C for 30 min, and washed twice with
PBS. After blocking remaining GAM binding sites with control
mIgG1 and mIgG2a (10 
 
m
 
g/ml final concentration), CD14-TC and
 
CD56-PE were added for phenotypic identification. After further in-
cubation and washes, cells were analyzed on the FACScan
 
®
 
.
 
Measurement of change in [Ca
 
2
 
1
 
]
 
i
 
.
 
Changes in intracellular [Ca
 
2
 
1
 
]
 
i
 
,
induced by cross-linking of purified NK cell Fc
 
g
 
RIIIa with heat-
aggregated human IgG or with anti-FcgRIIIa mAb, were determined
in purified indo-1-AM–loaded NK cells using an SLM 8000 spectro-
fluorometer and the simultaneous 405/490 nm fluorescence emis-
sion ratio as described previously (37, 38). Briefly, cells in suspension
at 107 cells/ml in Ca21- and Mg21-free PBS, pH 7.4, were incubated
with 5 mM indo-1-AM at 378C for 15 min and washed in PBS. Cell
preparations to be opsonized with mAb 3G8 were resuspended in
Ca21- and Mg21-free PBS at 107 cells/ml, incubated with saturating
concentrations of 3G8 (10 mg/ml) at 378C for 5 min, and washed in
PBS. All cells were resuspended in 1.1 mM Ca21, 1.6 mM Mg21 PBS
at 378C for 5 min and then immediately transferred to a continuously
stirring cell cuvette maintained at 378C in the SLM 8000. With excita-
tion at 355 nm, the simultaneous fluorescence emission at 405 and 490
nm was measured, integrated, and recorded each second. After estab-
lishing a base line for 60 s, either aggregated human IgG or goat
F(ab9)2 anti–mouse IgG was added at final concentrations of 20 or 35
mg/ml, respectively, and data acquisition was continued for an addi-
tional 3.5 min. Each sample was individually calibrated by lysing cells
in 1% Triton X-100 to determine the maximal emission ratio and by
adding EDTA (20 mM final concentration) to determine the minimal
ratio. The indo-1 fluorescence emission ratio was converted to [Ca21]i
by the method of Grynkiewicz (39).
Induction of NK cell IL-2 receptor (CD25) expression and cell via-
bility. Purified NK cells were cultured in RPMI/10% FCS and rIL-2
(100 U/ml) with or without a defined stimulus for varying periods of
time in 96-well plates. FcgRIIIa-mediated stimulation of NK cells was
effected either with the anti-FcgRIIIa mAb 3G8 IgG (10 mg/ml) or
with heat-aggregated human IgG (20 mg/ml). For mAb stimulation,
wells were precoated with 10 mg/ml F(ab9)2 GAM (Jackson Immu-
noResearch) for 2 h at 378C, rinsed, and 105 NK cells (106 cells/ml)
were added with mAb and incubated for various periods of time. Ag-
gregated human IgG was used either in solution as a soluble stimulus
or immobilized to the tissue culture plated (precoating for 2 h at
378C) before the addition of cells. Since induction of CD25 expres-
sion was observed within 1 h of stimulation as previously reported
(40, 41), we examined incubation periods ranging from 1 to 48 h.
CD25 expression was determined by flow cytometry using anti-CD25-
FITC (Caltag Laboratories).
Figure 1. Schematic representation of the 
FcgRIIIA genomic structure and cDNA 
structure showing the relative location of 
primers used for PCR-based sequencing 
(sequencing sets 1–4) and allele-specific 
PCR (PCR set 1). For sequencing analysis, 
an M13-based dye-primer sequencing 
strategy was used. FcgRIIIa encoding 
cDNA was prepared from purified MNC. 
Relative positions of nt 230 and 559 are 
shown. S, Signal sequence (encoded in two 
exons); TM/CY, transmembrane/cytoplas-
mic domains; 39-UT, 39 untranslated se-
quence.
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The viability of purified and 24-h IL-2–primed (100 U/ml) NK cells
after FcgRIIIa-mediated stimulation was determined by quantitation
of propidium iodide (PI) uptake in the FACScan® and by direct vi-
sual assessment of trypan blue exclusion. Significant changes in cell
viability could be detected within 1 h of stimulation with mAb or ag-
gregated IgG (42–44). To determine if FcgRIIIa-mediated stimula-
tion was inducing cell death via apoptosis, in selected experiments
cells were fixed, permeabilized, and analyzed for quantitative DNA
content. Subdiploid uptake of PI reflects cell death via apoptosis (45).
Additionally, we examined stimulated cells for apoptotic morphology
(chromatin condensation and nuclear fragmentation) (43) after fixa-
tion (2% paraformaldehyde plus 0.5% glutaraldehyde in 0.05 M ca-
codylate buffer, pH 7.2, followed by post-fixation with 1% osmic acid
in cacodylate buffer, pH 7.2). Cells were suspended in 1.5% agar, em-
bedded in Spurr’s resin, and the thin sections were viewed in a Phil-
lips CM-12 electron microscope.
Statistical analysis. Differences in ligand binding and mAb bind-
ing were analyzed by Student’s t test. The x2 test was used to analyze
Figure 2. Sequence analysis of a portion of 
FcgRIIIa cDNA from three normal do-
nors. FcgRIIIa encoding cDNA was pre-
pared from purified MNC and an M13-
based dye-primer sequencing strategy was 
used (see Methods). Donors homozygous 
for nt 559-T (A), homozygous for nt 559-G 
(C), and a donor heterozygous for nt
559-T/G (B) are shown. In each tracing, nt 
531 (*) is shown to indicate the presence of 
cDNA encoding the FcgRIIIA gene (C at 
nt 531) and not the FcgRIIIB gene (which 
is T at nt 531).
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the distribution of FcgRIIIA genotypes (corresponding to 176-V/V,
176-F/F, and 176F/V) in SLE and non-SLE controls. The null hypoth-
esis was rejected at the 95% confidence level (P , 0.05).
Results
FcgRIIIA sequence polymorphisms. The recent observation of
an FcgRIIIA sequence polymorphism on NK cells which influ-
ences ligand binding (24) raised the possibility that this se-
quence polymorphism might explain previously described dif-
ferences in NK FcgRIIIa and NK cell function (23). To test
this hypothesis we identified several of these normal donors
and characterized the nucleotide sequence of their FcgRIIIA.
The cell type specific expression of FcgRIIIA and FcgRIIIB in
NK cells/mononuclear phagocytes and in neutrophils, respec-
tively, provides a strategy for selective sequencing of cDNAs
derived from these two highly homologous genes. Further-
more, within the coding region of FcgRIII, there are 10 nucle-
otide differences between FcgRIIIA and FcgRIIIB that can be
used to confirm the presence of only FcgRIIIA or FcgRIIIB
sequence. Using this approach, two normal donors, one with
the low binding FcgRIIIa phenotype and one with a high bind-
ing FcgRIIIa phenotype (23), were both shown to be T/ T230
homozygotes. Interestingly, however, while the low FcgRIIIa
phenotype showed no differences from the conventional se-
quence, the donor characterized phenotypically as high binding
FcgRIIIa was heterozygous T/G at nt 559 (Fig. 2). This nucle-
otide difference, previously mentioned by Ravetch and Perus-
sia (21), raised the possibility that this nonconservative nucle-
otide polymorphism encoding a phenylalanine to valine at
amino acid residue 1762 in the membrane proximal EC2 of
FcgRIIIa might affect ligand binding and receptor function.
Sequence analysis of the entire coding region for MNC
FcgRIIIA cDNA from a total of 30 normal donors revealed
variation in nt position 559 (T or G). In this group, cDNAs
from three individuals contained only G559 while six donors
contained only T559. The remaining 21 donors were found to
contain both T559 and G559 (Fig. 2). All 30 normal donors were
homozygous T at nt 230 and homozygous C at nt 248 (24, 25).
There were no other sequence differences throughout the
whole FcgRIIIA gene except that two donors were heterozy-
gous at position 249 for a conservative G249 to A249 substitu-
tion, a silent variation at the third position of the codon for
serine. These data demonstrate that the sequence variation in
the FcgRIIIA gene at nt 559 (amino acid 176) is not a rare mu-
tation, but rather a common polymorphism.
Characterization of CD16 epitopes. To determine if the 176F
to V change affects the binding of anti-CD16 mAb which
might explain previously reported variations in anti-CD16
mAb reactivity (28, 30, 31, 46, 47), the reactivity of FcgRIIIa
on peripheral blood NK cells was characterized using a panel
of anti-CD16 mAb. Donors homozygous for 176F or 176V and
homozygous for 66L2 and 72S2 were examined by flow cytome-
try. Using the well characterized anti-CD16 mAb CLB-Gran1,
identical CD16 fluorescence intensities were observed on
CD56 positive NK cells from donors of both genotypes (Fig. 3
A and Table I). Similar results were evident with six additional
anti-CD16 mAbs (Table I) including mAb B73.1 which is af-
fected by the polymorphism at nt 230 (24, 25). mAbs 1D3 and
MEM154 showed differential binding to NK cells from donors
homozygous for F compared with V. In both instances, these
mAb bound well to 176V/V donors but only poorly to 176F/F
donors (Fig. 3, C and D, and Table I). mAb 3G8 showed subtle
differences which did not reach statistical significance with our
sample size (Fig. 3 B). These data indicate that although do-
nors homozygous for either the F or the V alleles express the
Figure 3. CD16 mAbs MEM154 and 1D3 
show differential reactivity with FcgRIIIa-
176V and FcgRIIIa-176F alleles. Lympho-
cytes and NK cells were identified in 
washed whole blood by characteristic light 
scatter properties and lack of reactivity 
with anti-CD14. Anti-CD16 staining on the 
CD142 lymphocytes is shown. Blood from 
donors homozygous for FcgRIIIa-176V/V 
and FcgRIIIa-176F/F was examined. Iden-
tical Gran1 reactivity (A) confirms identi-
cal receptor density between the two do-
nors. As previously reported, mAb 3G8 
binds slightly less to the FcgRIIIa-176F al-
lele than the FcgRIIIa-176V allele (the 
functional high binding phenotype, see Re-
sults) (B). mAbs 1D3 (C) and MEM154 
(D) bound well to NK cells from the
FcgRIIIa-176V/V donor but reacted 
poorly with NK cells from the FcgRIIIa-
176F/F donor. Data represent a single do-
nor pair out of a total of five different do-
nor pairs examined.
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same level of CD16 protein on the surface of NK cells, the re-
activities for some anti-CD16 mAbs differ, suggesting that the
these allelic proteins have different three-dimensional struc-
tural characteristics.
We then examined the mAb epitopes expressed on CD16
positive circulating monocytes. This population, typically a small
percentage of circulating monocytes (35), was identified by
multicolor fluorescence. Because FcgRIIIa expression by mono-
cytes is variable among donors, we sought donors homozygous
for 176F or 176V (and homozygous for both 66L and 72S) ex-
pressing comparable levels of mAb CLB-Gran1 reactivity on
their peripheral blood monocytes. In paired experiments, B73.1
showed identical reactivity while both 1D3 and MEM154
showed less reactivity with the 176 F/F donor (results not
shown).
Characterization of ligand binding. A single amino acid
change at residue 131 in the membrane proximal domain of
FcgRIIa (CD32) results in a nearly 10-fold alteration in quan-
titative ligand binding of human IgG2 (10–12). To determine if
the 176F/V polymorphism in the homologous extracellular do-
main of FcgRIIIa altered ligand binding, we examined the bind-
ing of pooled human IgG and of human IgG myeloma proteins
to peripheral blood leukocytes from our homozygous donors.
FcgRIIIa has a higher affinity for IgG than FcgRIIa and
FcgRIIIb. This higher affinity (reported to be in the range of
1–7 3 107 M21) is less than the affinity of IgG binding to FcgRIa,
but is sufficient to allow binding of monomer IgG at physiolog-
ical concentrations. Binding of pooled human IgG to NK cells
was observed in all donors, but the level of binding was sub-
stantially different between our homozygous donor groups. In-
dividuals homozygous for both 176V and 66L bound signifi-
cantly more IgG1 and IgG3 than did donors homozygous for
both 176F and 66L (Fig. 4). The difference in binding of IgG1
and IgG3 was observed at both concentrations of IgG (15 and
30 mg/ml) used in these studies. Binding of the myeloma pro-
teins to CD56 positive NK cells was completely blocked by the
anti-CD16 mAb CLB-Gran1 (results not shown). A difference
in binding of IgG4 (30 mg/ml) was also observed; there was de-
tectable but low binding to donors homozygous for 176V but
not 176F. mAb CLB-Gran1 was used to confirm identical lev-
els of CD16 protein on the NK cell surface (Fig. 3). No binding
of IgG2 (30 and 15 mg/ml) or IgG4 (15 mg/ml) to NK cells from
either donor type was observed.
In a number of experiments, we were also able to observe
hIgG myeloma protein binding to FcgRIIIa on the small sub-
set of human monocytes expressing CD16. Using preincuba-
tion with anti-CD64 mAb 197 to block the high affinity FcgRIa,
binding of human IgG to FcgRIIIa could be quantitated. Com-
plete blockade of FcgRIa was confirmed by showing that the
binding of mIgG2a (30 mg/ml) was reduced to background au-
tofluorescence levels in the presence of mAb 197 (Fig. 5 C). In
paired experiments with donor monocytes matched for CLB-
Gran1 reactivity and with FcgRIa blocked by mAb 197, 176V
homozygous donors bound more hIgG1 than did donors ho-
mozygous for 176F (Fig. 5, A and B). These data document
that the nt 559 polymorphism of FcgRIIIA which changes a
single amino acid in EC2 results in a change in apparent affin-
ity for ligand binding independent of the cell type in which it is
expressed.
Functional implications of the 176F/V polymorphism. To de-
termine if the difference in quantitative binding of ligand to
the 176F and 176V alleles results in differences in receptor
Table I. CD16 Epitopes
mAbs mAb subclass
Donor type
FcgRIIIa-176V/V FcgRIIIa-176F/F
n 5 5 n 5 5
CLB-Gran1 mIgG2a 1769696 16736191
GRM 1 mIgG2a 12786108 1356664
B73.1 mIgG1 1059615 11136138
Leu11a mIgG1 337625 395672
3G8 mIgG1 552669 399676
30.2 mIgG1 803650 698660
214.1 mIgG1 77617 89614
135.9 mIgG1 945658 802626
MEM154* mIgG1 11696126 4866
ID3‡ mIgM 70615 34615
Reactivity of anti–human CD16 mouse mAbs with NK cells expressing
the different allelic forms of FcgRIIIa. Data shown are mean channel
fluorescence6SEM. ‡P , 0.003, FcgRIIIa-176V/V vs. -176F/F; *P ,
0.001, FcgRIIIa-176V/V vs -176F/F.
Figure 4. Binding of human IgG myeloma proteins to NK cell
FcgRIIIa on donors homozygous for 176V/V and 176F/F. NK cells in 
washed whole blood were identified by characteristic light scatter 
properties, by reactivity with anti-CD56, and by lack of reactivity 
with anti-CD14. Binding of FITC-labeled human IgG1 (A) and IgG3 
(B) (each at 30 mg/ml) to CD561/CD142 cells is shown. NK cells from 
each donor expressed identical levels of CD16 (using mAb Gran1). 
Data represent a single donor pair out of a total of five different do-
nor pairs that were examined.
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function, we quantitated FcgRIIIa-induced NK cell activation.
Cross-linking of FcgRIIIa results in an immediate rise in [Ca21]i
(48, 49). When purified NK cells from 176F and 176V homozy-
gous donors were stimulated with the anti-CD16 mAb 3G8
and F(ab9)2 GAM, a brisk rise in [Ca21]i was observed. The
magnitude of this rise in [Ca21]i in the homozygous donors was
indistinguishable (466 and 516 nM in the 176F and 176V ho-
mozygous donors, respectively; Fig. 6). When aggregated hu-
man IgG was used as the stimulus, a rapid rise in [Ca21]i was
also observed in the homozygous donors, but the magnitude of
the rise in NK cells from the 176V homozygote donor was
more than threefold greater than the rise observed in NK cells
from the 176F homozygote donor (56 and 189 nM in the 176F
and 176V homozygous donors, respectively; Fig. 6).
To examine the impact of the 176F/V polymorphism on in-
tegrated cell functions, upregulation of surface CD25 (IL-2 recep-
tor) on IL-2–treated NK cells after engagement of FcgRIIIa
was assessed (40, 41). Stimulation with mAb 3G8 and F(ab9)2
GAM induced rapid upregulation of expression of CD25 (IL-
2R) on the surface of purified NK cells. Using purified NK
cells from homozygous donors, engagement and cross-linking
of CD16 with IgG aggregates also resulted in rapid upregula-
tion of CD25 expression. However, donors homozygous for
176V showed significantly higher levels of CD25 expression
relative to donors homozygous for 176F (Fig. 7).
FcgRIIIa on NK cells is important in regulating NK cell
survival through receptor-mediated activation-induced cell
death (42–44). Both anti-CD16 mAb plus GAM cross-linker
and IgG aggregates decreased NK cell survival quite rapidly.
However, while comparable levels of cell survival were appar-
ent after anti-CD16 mAb stimulation, there was a marked dif-
ference between 176F/F and 176V/V donors in the degree of
NK cell death after stimulation with IgG aggregates (Fig. 8).
Nuclear fragmentation and chromatin condensation, charac-
teristic of apoptosis and assessed by transmission electron mi-
croscopy, was observed in NK cells stimulated via FcgRIIIa
(with cross-linked mAb or aggregated IgG) (results not shown).
In addition, quantitative PI staining of fixed and permeabilized
cells demonstrated a distinct population of apoptotic cells with
subdiploid DNA content in aggregated IgG stimulated but not
control cells (Fig. 9).
Characterization of the 176F/V polymorphism in donors with
disparate antibody-dependent cellular cytotoxicity (ADCC) ac-
tivity. Because of the clearly defined differences in FcgRIIIa-
induced function in our homozygotes, we considered the possi-
bility that the differences in quantitative ADCC by NK cells of
different donors, previously described by Vance (23), might re-
flect the 176F/V polymorphism. This possibility was reinforced
by the original observation that the difference in ligand bind-
ing among these donors was much greater than the difference
in mAb 3G8 binding. Accordingly, we made cDNA from
MNC preparations from six previously characterized individu-
als. Four low binding FcgRIIIa phenotype donors were ho-
mozygous for T559 (176F), for T230 (66L), and for C248 (72S)
while the two other donors, characterized phenotypically as
high binding FcgRIIIa, were G/T559 heterozygous and ho-
mozygous for T230 (66L) and for C248 (72S) indicating that NK
cell ADCC is influenced by the 176F/V polymorphism (23).
These data demonstrate the functional importance of variation
of nt 559 in an independently phenotyped group of donors.
Association of the 176F allele with autoimmune disease.
We have shown previously that the low binding allele of FcgRIIa
(131H) is associated with SLE and nephritis in African-Ameri-
can patients (16). To determine if skewing of the normal
176F/V allelic system might also be associated with SLE, we
developed a genotyping assay based on allele-specific PCR.
Figure 5. Binding of human IgG1-FITC (30 mg/ml) to peripheral 
blood monocyte FcgRIIIa on donors homozygous for 176V/V (A) 
and 176F/F (B). Monocytes in washed whole blood were identified by 
characteristic light scatter properties, by reactivity with anti-CD14 
(bright and dim), and by lack of reactivity with anti-CD56. The ligand 
binding site of the high affinity FcgRI was blocked by preincubation 
with mAb 197. Complete blockade of ligand binding (mIgG2a) is 
shown (C). Monocytes from each donor expressed identical levels of 
CD16 (using mAb Gran1). Data represent a single donor pair out of 
a total of four different donor pairs that were examined. Monocytes 
from the fifth donor pair did not show significant reactivity with anti-
CD16. Background fluorescence levels are lower in C because of 
lower detector settings used for the mAb binding panel.
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The fidelity of this assay was established using a genomic tem-
plate from our initial group of FcgRIIIa sequenced normal do-
nors (n 5 30) and confirmed by the sequencing of selected
SLE patients (n 5 38) and additional normal donors (n 5 11).
Using this assay, we genotyped a population of 200 ethnically
diverse patients with documented SLE and a cohort of 113
ethnically diverse normal individuals. There was a significant
skewing in the distribution of the three genotypes (3 3 2 con-
tingency table, x2 5 9.87, P , 0.01; Table II) and in the allelic
frequency (2 3 2 contingency table, x2 5 6.13, P , 0.015; Ta-
ble II) between the two groups. In the SLE patients, there was
an increase in homozygosity for 176F; 44% of the 200 SLE pa-
tients but only 23% in the 112 non-SLE control subjects were
176F homozygous. In contrast, only 4% of the 79 SLE patients
with nephritis were 176V/V homozygotes compared with 15%
of the 121 nonrenal SLE patients (15% in normal controls).
These results suggest that the presence of the FcgRIIIa 176F
allele is a significant risk factor for development of SLE, espe-
cially with nephritis.
Discussion
The recent observation of an FcgRIIIA sequence polymor-
phism on NK cells which influences ligand binding (24) raised
the possibility that this sequence polymorphism might explain
previously described differences in NK FcgRIIIa and NK cell
function (23). To test this hypothesis we identified several of
these normal donors and characterized the nucleotide se-
quence of their FcgRIIIA. Contrary to our expectation, these
donors were monomorphic at nt 230 and nt 248 but polymor-
phic at nt 559. This polymorphism predicts an F to V substitu-
tion in position 176 of EC2 of FcgRIIIA, the domain which is
critical for ligand binding. Normal donors, homozygous for F
and for V at position 176 and homozygous for L at position 66
and for S at position 72 in all cases, were characterized for
ligand binding and for FcgRIIIa function. NK cells and mono-
cytes from donors with 176V/V bound more IgG1 and IgG3
than the corresponding cells from 176F/F donors. FcgRIIIa-
176V/V elicited a larger flux in [Ca21]i, a greater degree of cell
activation, and a more pronounced program of activation-
induced cell death than FcgRIIIa-176F/F. FcgRIIIa-176F/F in-
dividuals were overrepresented in a population of 200 SLE
patients while FcgRIIIa-176V/V individuals were underrepre-
sented among patients with nephritis. These data, coupled with
other observations (14–20), suggest an important role for
FcgR polymorphisms in human disease.
The absence of the V allele in the phenotypic low binding
donors and its presence in the high binding donors strongly
Figure 6. Aggregated hIgG and anti-CD16 mAb 3G8 induced rise in intracellular Ca21 levels in purified NK cells from donors homozygous for 
FcgRIIIa-176V/V and FcgRIIIa-176F/F. Cells were isolated using a magnetic negative depletion strategy (Miltenyi NK Cell Isolation Kit) and 
were . 90% CD56 and CD16 positive after isolation. NK cells were loaded with indo-1-AM and stimulated at 60 s with either 60 mg/ml aggre-
gated hIgG (left) or were prelabeled with mAb 3G8 F(ab9)2 and then stimulated with F(ab9)2 GAM at 60 s (right). In all experiments, the rise in 
[Ca21] induced with aggregated hIgG is much larger in the FcgRIIIa-176V/V donor (mean peak [Ca21] (nM) above baseline in 176V/V and
176F/F donors; 199621 and 67611, respectively, P , 0.01, n 5 3). Indistinguishable changes in [Ca21] in both donors were induced by cross-
linked mAb 3G8 (mean peak [Ca21] (nM) above baseline in 176V/V and 176F/F donors; 555651 and 5266137, respectively, P . 0.05, n 5 3).
A representative experiment of three (with different donor pairs) is shown.
Novel Polymorphism of FcgRIIIa (CD16) and Autoimmune Disease 1067
suggest that this polymorphism explains the difference in NK
FcgRIIIa originally described by Vance and colleagues (23). In
that cohort, the tendency toward lower reactivity with mAb
3G8 among low binders is consistent with our data demon-
strating the same subtle trend (Fig. 3 B and Table I). Most im-
portantly, in the Vance study the ratio of IgG binding to mAb
3G8 reactivity clearly shows reduced ligand binding, even
when mAb 3G8 is used to define receptor number. Less clear,
however, is the relationship between the 176F/V polymor-
phism and the NK FcgRIIIa described in several patients with
recurrent infections (26). Both of those patients showed mark-
edly reduced reactivity with mAb B73.1. Based on our data
that the B73.1 epitope is not influenced by position 176 and
other data indicating that 66R/R donors have markedly re-
duced levels of B73.1 reactivity (24), we anticipate that these
individuals with recurrent infections have some difference in
NK cell FcgRIIIa other than variation at position 176. Indeed,
the polymorphism at amino acid position 66 may contribute to
this difference (26). Quantitatively, however, the approximate
twofold increase in IgG1 binding reported for donors with 66R
or 66H compared with 66L parallels the magnitude of the dif-
ference in IgG binding we have seen with 176V compared with
176F. Although differences in ligand binding can influence sus-
ceptibility to infection (14, 15), this functional similarity be-
tween the polymorphisms at 66 and 176 and the prevalence of
the 176F/V polymorphism makes this mechanism an unlikely
basis for the rare patients described to date (26). However, the
similarity in ligand binding raises the interesting question of
whether the difference in ligand binding described for donors
varying in position 66 might be explained by allelic association
with position 176. To date, in more than 80 normal donors, we
have identified only two individuals who are heterozygous T/G
at nt 230 (66L/66R), one individual who is heterozygous T/A at
nt 230 (66L/66H), and one individual who is homozygous at nt
230 for the uncommon A allele (66H). Therefore, we have
been unable to test the hypothesis that 66R and 66H occur in
association with 176V and that 176V may determine the ligand
binding phenotype.
There are several interesting implications of the FcgRIIIa
176F/V polymorphism. Recent data have suggested that FcgR
expressed on macrophages may play an important role in the
regulation of serum IgG levels. Initial observations in the
FcgRII knockout mouse demonstrated an impact on total IgG
levels, but since the entire FcgRII gene with its various splice
Table II. Distribution of FcgRIIIa Alleles in SLE Patients and 
Non-SLE Controls
SLE patients Non-SLE controls
n 5 200 n 5 113
Genotype*
No. of subjects (% of group)
176F/F 87 (44%) 29 (26%)
176F/V 92 (46%) 69 (61%)
176V/V 21 (10%) 15 (13%)
Allelic frequency‡
176F 0.67 0.56
176V 0.33 0.44
A PCR-based genotyping assay (using genomic DNA) was developed
using allele specific primers (see Results). 200 ethnically diverse patients
with documented SLE (33) and 113 ethnically diverse normal volunteers
were genotyped for FcgRIIIa alleles [nt 559G (176V) and/or nt 559T
(176F)]. Allele and gene frequencies are shown. *SLE patients vs. nor-
mal controls; 3 3 2 contingency table, x2 5 9.87, P , 0.01; ‡SLE patients
vs. normal controls; 2 3 2 contingency table, x2 5 6.13, P , 0.015.
Figure 7. Aggregated hIgG and anti-CD16 mAb 3G8 induced upreg-
ulation of CD25 expression on purified NK cells from donors ho-
mozygous for FcgRIIIa-176V/V and FcgRIIIa-176F/F. Cells were iso-
lated using a magnetic negative depletion strategy (Miltenyi NK Cell 
Isolation Kit) and were . 90% CD56 and CD16 positive after isola-
tion. CD25 expression was determined after cells were primed over-
night with IL-2 (100 U/ml) and a with subsequent 2-h stimulation 
with either 60 mg/ml aggregated hIgG (A), anti-CD16 mAb 3G8
(2.5 mg/ml) on GAM-coated plates (B), or buffer as control (C). Data 
illustrated represent a single donor pair out of four different donor 
pairs that were examined. The mean percent CD25 positive cells after 
aggregated hIgG stimulation was 66.468.8 for 176V/V donors and 
34.9619.4 for 176F/F donors (P , 0.03). Stimulation of NK cells from 
176V/V and 176F/F donors with anti-CD16 mAb consistently pro-
duced a change in mean percent CD25 positive cells relative to con-
trol but there was no significant difference in the level of induction 
between donors (P . 0.05).
1068 Wu et al.
isoforms was disrupted, the relative roles of FcgRIIb1 ex-
pressed on B cells as opposed to FcgRIIb2 expressed on mac-
rophages could not be determined (50). Somewhat surpris-
ingly, the naturally occurring disruption of the expression of
the FcgRIIb2 isoform expressed on macrophages of NOD
mice is strongly associated with upregulation of both IgG1 and
IgG2b serum levels despite relatively normal expression of the
B cell specific FcgRIIb1 (51). The possibility that macrophage
FcgR may be playing an important role in the regulation of
IgG levels is further underscored by the observation in hu-
mans that different alleles of FcgRIIa are associated with dif-
ferent serum levels of IgG2 (14). This observation is particu-
larly important because in humans, FcgRIIa is expressed on
macrophages but not on B cells. Furthermore, this observation
emphasizes that alleles with different capacities to bind human
IgG2, not just presence or absence of receptor, are associated
with different levels of IgG. Thus, it seems reasonable to ex-
trapolate to the prediction that the FcgRIIIa 176F/V alleles
may influence the level of IgG1 and IgG3. How they influence
specific responses to vaccination and net effective humoral im-
munity remains to be determined.
Of course the implications of the FcgRIIIa 176F/V poly-
morphism extend beyond the regulation of serum IgG levels.
Soluble FcgRIIIa is clearly present in the circulation (52–54).
In a number of systems, soluble receptor can influence the
level of B cell activation presumably through binding surface
immunoglobulin (55, 56). Since FcgRIIIa binds ligand with
higher affinity than FcgRIIIb which is unable to bind ligand in
monomeric form, FcgRIIIa may play a particularly important
role in mediating these effects. FcgRIIIa may also play a criti-
cal role in the first-dose cytokine-release syndrome seen with
some therapeutic monoclonal antibodies (57). Furthermore,
our earlier studies in a primate model of immune complex
handling demonstrated an essential role for FcgRIIIa (58, 59),
and more recent observations in mice with targeted disruption
of murine FcgRIII also support an important role in immune
complex–mediated triggering of inflammatory reactions (60).
Since each of these effects is dependent on binding of IgG, the
potential for FcgRIIIa 176F/V alleles to influence the biologic
potential of both receptor and ligand is clearly evident.
To directly test this potential in human biology in vivo, we
investigated the possibility that FcgRIIIa 176F/V alleles might
be abnormally represented in patients with SLE, a prototypic
immune complex disease. A role for abnormal FcgR function
in SLE has been described (61), and the skewing of FcgRIIa
alleles in SLE has supported the hypothesis that the FcgRIIa
allele with a low binding phenotype for human IgG2 would be
overrepresented in SLE (16, 17). In most immune complexes,
however, autoantibodies are not of the IgG2 isotype but rather
of the IgG1 and IgG3 isotypes. Thus, one might anticipate an
overrepresentation of 176F and an underrepresentation of
176V in immune complex disease. In our study of 200 ethni-
cally diverse SLE patients, this skewing was very apparent
(Table II). Indeed, in patients with SLE and nephritis, the ho-
mozygous 176V was underrepresented by more than fourfold
compared with those without nephritis. We recognize that
these observations need confirmation in large independent
populations, that further stratification by clinical phenotype
and ethnicity may be insightful, and that studies of multiplex
families will be informative. We also recognize that this asso-
ciation may result from linkage to a different gene at another
locus. However, the biology of this polymorphism, its rele-
vance to the pathophysiology of SLE, and the coincidence of
FcgRIIIa’s chromosomal location with a region of high inter-
est in the microsatellite-based scanning of the genome in SLE
patients (62, 63), all make FcgRIIIa a likely gene for SLE dis-
ease risk.
Based on the biology of the FcgRIIIa-176F/V polymor-
Figure 8. Aggregated hIgG 
and anti-CD16 mAb 3G8 in-
duced cell death of purified
NK cells from donors homozy-
gous for FcgRIIIa-176V/V 
and FcgRIIIa-176F/F. Cells 
were isolated using a magnetic 
negative depletion strategy 
(Miltenyi NK Cell Isolation 
Kit) and were . 90% CD56 
and CD16 positive after isola-
tion. Cell viability was deter-
mined in the presence of try-
pan blue by cell counting by 
two independent observers. 
NK cells were stimulated for 24 h with IL-2 (100 U/ml) and then sub-
sequently with buffer as control (open bars), anti-CD16 mAb 3G8 
(2.5 mg/ml) on GAM-coated plates (striped bars), or 60 mg/ml aggre-
gated hIgG (hatched bars). The mean number of cells remaining 
(6SEM, n 5 4) for 176V/V donors after aggregated IgG stimulation 
was significantly less than for 176F/F donors (P , 0.05); the two 
groups were not different in control and anti-CD16 stimulation con-
ditions.
Figure 9. Stimulation of purified IL-2 
primed NK cells with hIgG aggregates in-
duces the appearance of a subdiploid pop-
ulation of cells characteristic of apoptotic 
cells. After overnight incubation with IL-2 
(100 U/ml), cells were treated with buffer 
(A) or IgG aggregates (B) for 1 h, 378C. 
Cells were then fixed, permeabilized, and 
stained for quantitative DNA content with 
PI (see Methods). To allow discrimination 
of cell doublets, PI width and PI area were 
collected and cell fragments were excluded 
through analysis of SSC (side light scatter) 
and FSC (forward light scatter).
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phism, one can imagine that it could influence many antibody-
mediated responses involving IgG1 and IgG3. Since FcgRIIIa
is expressed on NK cells, mononuclear phagocytes, and renal
mesangial cells, host defense against viral, bacterial, and other
pathogens could be affected. Antibody-mediated immune sur-
veillance could be altered as well as the interaction with im-
mune complexes. Furthermore, the therapeutic response to in-
travenous gammaglobulin might vary in accordance with the
FcgRIIIa-176F/V polymorphism. Indeed, characterization of
Fcg receptor genotypes, in conjunction with other properties
of the humoral immune response such as antibody subclass
and complement status, may provide essential insights into
vaccine effectiveness and disease risk.
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